Capital Increase in Genmab as a Result of Employee Warrant Exercise

| Source: Genmab A/S

Company Announcement

Copenhagen, Denmark; August 20, 2014 – Genmab A/S (OMX: GEN) will increase its share capital by 134,005 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

  • 3,200 shares at DKK 40.41,
  • 32,125 shares at DKK 46.74,
  • 750 shares at DKK 66.60,
  • 160 shares at DKK 67.50,
  • 438 shares at DKK 68.65,
  • 300 shares at DKK 80.55,
  • 1,000 shares at DKK 89.50,
  • 125 shares at DKK 97,
  • 10,000 shares at DKK 101,
  • 65,875 shares at DKK 114,
  • 562 shares at DKK 116,
  • 13,220 shares at DKK 129.75, and
  • 6,250 shares at DKK 147.50.

Proceeds to the company are approx. DKK 13.1 million. The increase corresponds to approx. 0.2 % of the company's share capital.

The increase includes the exercise of 6,250 warrants by Chairman of the Board of Directors Mats Pettersson and the exercise of 4,375 warrants by board member Burton G. Malkiel.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2014. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority. Genmab A/S' current share capital amounts to DKK 56,687,266 and will after the capital increase be DKK 56,821,271. The capital increase is expected to be finalized shortly.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications, a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E:

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody™ and UniBody®. Arzerra® is a registered trademark of the GSK group of companies.

Company Announcement no. 41
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K